Clinical trials: CD - Crohn's Disease
Crohn's Disease
Controlled Trial of 4-Aminosalicylic Acid in Patients With Small Bowel Crohn's Disease
OBJECTIVES: I. Assess the efficacy and safety of 4-aminosalicylic acid in patients with active Crohn's disease of the small bowel.
- Trial name
- NCT00004423
- Testing
- -aminosalicylic acid
- Volunteers
- 80 people
- Sponsor
- University of Vermont
Crohn Disease, Anal Fistula
Study on the Treatment of Anal Fistulas Using Alofisel Versus Fat Autologous Stem Cells
One of the newest and most innovative medicinal approaches is cell therapy. Several clinical trials and experimental investigations have looked into the feasibility of treating CD-related fistulas with stem cells.
- Trial name
- CHAZAM (NCT05974280)
- Testing
- Alofisel, Fat stem cell
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Nantes University Hospital
Perianal Fistula, Primary; Complex
Follow-up Study of Autologous Adipose-derived Stem Cells (ANTG-ASC) for the Complex Fistula (ANTG-ASC-211)
This is an open follow-up clinical trial to evaluate a sustained efficacy and safety of ANTG-ASC injection for 4 months (6 months after final dose injection) after Phase II clinical trial.
- Trial name
- ANTG (NCT01623453)
- Testing
- Autologous adipose derived stem cells(low dose group), Autologous adipose derived stem cells(high dose group)
- Where
- 2 sites in South Korea
- Volunteers
- 6 people
- Sponsor
- Anterogen Co., Ltd.
Inflammatory Bowel Diseases, Colitis, Ulcerative
A Study of Kynteles Injection (Vedolizumab) in Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease or Chronic Pouchitis
In this study, participants with ulcerative colitis or Crohn's disease or pouchitis will be treated with Kynteles injection (Vedolizumab) according to their clinic's standard practice.
- Conditions
- Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease
- Trial name
- NCT04799496
- Where
- 43 sites in South Korea
- Volunteers
- 688 people
- Sponsor
- Takeda
Axial Spondyloarthritis, Crohn Disease
MRE as a Screening Tool for axSpA in IBD
This study aims to assess the effectiveness (specificity and sensitivity) of using magnetic resonance enterography (MRE) as a screening tool for axial spondyloarthritis (axSpA) in patients with Crohns disease.
- Trial name
- ProSpA-CD (NCT03817983)
- Testing
- MRE review for evidence of axSpA in SIJs, Clinical assessment and dedicated MRI of the spine and pelvis
- Where
- United Kingdom
- Volunteers
- 259 people, healthy volunteers welcome
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Crohn Disease
Whole-Food, Plant-Based Diet for Active Crohn's Disease
The purpose of this study is to assess the ability of a whole-food, plant-based (WFPB) diet to produce symptomatic remission in Crohn's Disease patients.
- Trial name
- NCT04982666
- Testing
- Whole-Food, Plant-Based Diet, FODMAP Diet
- Sponsor
- Mayo Clinic
Crohn's Disease
A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection
The purpose of this study is to evaluate the effectiveness of guselkumab treatment compared with placebo (an inactive substance with no medicine) in preventing recurrence of Crohn's disease in participants after surgery.
- Trial name
- PROGRESS (NCT05784129)
- Testing
- Guselkumab
- Where
- 11 sites in United States, Poland
- Volunteers
- 4 people
- Sponsor
- Janssen Research & Development, LLC
Crohn's Disease, IBD
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
This study (UNITI-1) will compare the effects (both positive and negative) of an initial treatment with ustekinumab to placebo over 8 weeks, in patients with moderately to severely active Crohn's disease who have either failed or…
- Conditions
- Crohn's Disease, IBD, Colitis, Inflammatory Bowel Disease
- Trial name
- NCT01369329
- Testing
- Group 2 ustekinumab 130 mg, Group 3: ustekinumab approximately 6 mg/kg
- Where
- 175 sites in United States, Australia and 21 more
- Volunteers
- 769 people
- Sponsor
- Janssen Research & Development, LLC
Inflammatory Bowel Disease
Distribution of a Single IV Dose Of [124I]-Pf 06687234 and Pf 06687234 Assessed With PET-CT Imaging In Moderate To Severe Ulcerative Colitis and Crohn's Disease
The purpose of the study is to evaluate the PK, safety and tolerability of PF-06687234 and [124I]IB-PF-06687234 (simultaneously given) in subjects with moderate to severe Ulcerative Colitis or Crohn's Disease.
- Trial name
- NCT03414788
- Testing
- PF 06687234, [124I]IB PF 06687234
- Where
- United States
- Sponsor
- Pfizer
Crohn's Disease
Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease
The primary objective of this study is to evaluate the long-term tolerability and safety of natalizumab when administered a dose of 300 mg intravenously (IV) to subjects with Crohn's Disease who have previously participated in…
- Trial name
- NCT00280956
- Testing
- natalizumab
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Biogen
Crohn's Disease
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
This study will evaluate the effectiveness and safety of the investigational drug 683699 in treating subjects with moderately to severely active CD (Crohn's Disease).
- Trial name
- NCT00101946
- Testing
- 683699
- Where
- 19 sites in United States, Canada
- Volunteers
- 17 people
- Sponsor
- GlaxoSmithKline
Crohn's Disease, Inflammatory Bowel Diseases
Beta-Hydroxybutyrate Feasibility Treating IBD
This clinical trial aims to understand the feasibility of patients taking ketone body supplement beta-hydroxybutyrate (BHB) for 4 weeks with a confirmed diagnosis of Crohn's disease and starting new therapy for active disease.
- Trial name
- BHB (NCT06351124)
- Testing
- Feasibility of beta-hydroxybutyrate supplementation to reduce inflammation in patients with Crohn's
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Texas at Austin
Abdominal Pain, Rectal Bloodloss
Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD
RATIONALE: A substantial proportion of children and teenagers with suspected inflammatory bowel disease (IBD) referred for endoscopy do not have the disease.
- Conditions
- Abdominal Pain, Rectal Bloodloss, Diarrhea, Inflammatory Bowel Disease
- Trial name
- CACATU (NCT02197780)
- Where
- 19 sites in Belgium, Netherlands
- Volunteers
- 355 people
- Sponsor
- University Medical Center Groningen
Crohn's Disease, Obesity
Crohn's Disease, Obesity and Disease Severity
The aim of our study is to suggest possible underlying mechanisms for the observed clinical differences in disease severity and behavior of overweight and obese patients with crohn's disease(BMI > 25 kg/m²)as compare to non-obese…
- Trial name
- CROHN_OBESE (NCT00488085)
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Crohn's Disease
B0151005 Open-Label Extension Study
This is a multi-center Phase 2, open label, safety extension study in subjects with moderate to severe CD who are anti-TNF inadequate responders.
- Trial name
- ANDANTE II (NCT01345318)
- Testing
- PF-04236921
- Where
- 127 sites in United States, Australia and 14 more
- Volunteers
- 191 people
- Sponsor
- Pfizer
Inflammatory Bowel Disease (IBD), Crohn's Disease
Efficacy and Safety of Low-Dose Upadacitinib Combined With Ustekinumab in the Treatment of Refractory Crohn's Disease
A multicenter retrospective study evaluating the effectiveness and safety of ustekinumab combined with low-dose upadacitinib in patients with refractory Crohn's disease.
- Trial name
- NCT07697547
- Testing
- Upadacitinib, Ustekinumab (UST)
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Shanghai 10th People's Hospital
Crohn's Disease
Pravastatin Therapy in Patients With Active Crohn's Disease: A Pilot Study
The primary objective of this study is to provide data regarding clinical and immunologic activity of oral doses of pravastatin 80mg administered daily for 6 consecutive weeks, for the treatment of active Crohn's disease as shown…
- Trial name
- NCT00599625
- Testing
- Pravastatin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Virginia
Ulcerative Colitis (UC), Crohn Disease (CD)
VedAryo® (Vedolizumab) Effectiveness and Safety Evaluation
The aim of this observational study is to evaluate Effectiveness and safety of VedAryo® (Vedolizumab) in male or female participants with clinical diagnosis of Inflammatory Bowel Disease. The main questions are aim to answer: 1.
- Conditions
- Ulcerative Colitis (UC), Crohn Disease (CD), Inflammatory Bowel Disease (IBD)
- Trial name
- NCT07273760
- Testing
- Vedolizumab
- Where
- 12 sites in Iran
- Volunteers
- 150 people
- Sponsor
- AryoGen Pharmed Co.
Inflammatory Bowel Disease, Crohn's Disease
Endoscopy and Endomicroscopy for Assessment of Mucosal Healing in Inflammatory Bowel Disease (IBD)
Inflammatory bowel disease (IBD) encompasses two major forms of chronic intestinal disorders, Crohn's disease and ulcerative colitis (UC).
- Conditions
- Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
- Trial name
- NCT01524120
- Testing
- Endoscopy (EPK-i, Pentax, Tokyo, Japan), Endomicroscopy (iCLE, Pentax, Tokyo, Japan)
- Where
- Germany
- Sponsor
- University of Erlangen-Nürnberg Medical School
Crohn's Disease
COmparison of MicroBiota AccordIng to Age in Crohn's Disease (COMeBACk)
The cause of CD could be different according to age at onset of CD symptoms. Indeed we know that some very young patients at CD diagnosis have particular genetic variants as abnormalities of the IL10R that are regarded as quite…
- Trial name
- COMeBACk (NCT02839317)
- Testing
- Biological
- Where
- 5 sites in France
- Volunteers
- 214 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille